Insulin detemir - Biologic Drug Details

Summary for insulin detemir

Tradenames:	1
High Confidence Patents:	14
Applicants:	1
BLAs:	1
Suppliers: see list	2
Recent Clinical Trials:	See clinical trials for insulin detemir

Recent Clinical Trials for insulin detemir

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Novo Nordisk A/S	PHASE4
Novo Nordisk A/S	PHASE1
Loyola University	PHASE3

See all insulin detemir clinical trials

Pharmacology for insulin detemir

Ingredient-type	Insulin
Established Pharmacologic Class	Insulin Analog

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for insulin detemir Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for insulin detemir Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536	10,220,155	2026-07-17	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536	10,357,616	2037-11-17	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536	10,376,652	2037-02-24	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536	11,097,063	2039-01-17	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536	11,311,679	2039-06-25	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for insulin detemir Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536	10,016,338	2036-12-20	Patent claims search
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536	10,241,117	2038-04-27	Patent claims search
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536	10,251,957	2032-06-01	Patent claims search
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536	10,265,291	2037-02-13	Patent claims search
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536	10,328,157	2037-02-03	Patent claims search

International Patents for insulin detemir

Country	Patent Number	Estimated Expiration
European Patent Office	2373361
Japan	4404380
Austria	E439883
Spain	2331202
Germany	602006020453

Supplementary Protection Certificates for insulin detemir

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C00214826/01	Switzerland		FORMER REPRESENTATIVE: E. BLUM AND CO. PATENTANWAELTE, CH
28/2004	Austria		PRODUCT NAME: INSULIN-DETEMIR UND PHARMAZEUTISCH ANNEHMBARE ZN-SALZE DAVON; NAT. REGISTRATION NO/DATE: EU/1/04/278/001-009 20040601; FIRST REGISTRATION: LI 56370 56371 56372 20031110
CA 2004 00029	Denmark		PRODUCT NAME: INSULIN DETEMIR
SZ 50/1999	Austria		PRODUCT NAME: INSULIN ASPART
SZ 28/2004	Austria		PRODUCT NAME: INSULIN-DETEMIR UND PHARMAZEUTISCH ANNEHMBARE ZN-SALZE DAVON

Market Dynamics and Financial Trajectory for Insulin Detemir

Last updated: February 19, 2026

What Is Insulin Detemir’s Market Position?

Insulin detemir, a long-acting basal insulin analog, generated approximately $2.4 billion in global sales in 2022, accounting for 16% of the estimated $15 billion insulin market.[1] Its primary competitors include insulin glargine and insulin degludec.

Manufactured by Novo Nordisk, the product holds a dominant share in multiple markets due to early regulatory approval, established efficacy, and proven safety profiles. Its use is concentrated in type 1 and type 2 diabetes management.

How Has the Market Evolved in Recent Years?

The insulin market has exhibited consistent growth driven by:

• Rising prevalence of diabetes: Estimated 537 million adults globally in 2021, expected to reach 643 million by 2030.[2]
• Adoption of basal insulins: Long-acting insulins account for approximately 70% of basal insulin prescriptions.[3]
• Competitive innovations: Insulin degludec and biosimilar glargine versions have entered the market, exerting pricing pressures.

In 2017, insulin detemir held approximately 20% of the insulin market. By 2022, its share declined slightly due to increased competition but remained significant. The average annual growth rate for insulin detemir from 2018 to 2022 stood at roughly 4%, outperforming some biosimilar and countertop options but losing ground to newer long-acting formulations.

How Do Pricing and Reimbursement Impact Sales?

Pricing is influenced by market regulations, payer negotiations, and biosimilar entries. List prices for insulin detemir are around $85 per pen in the United States. Reimbursement rates vary by country:

• United States: Limited copays under insurance plans, cooperation with PBMs.
• European Union: Negotiated discounts, leading to a 15–25% price reduction compared to list prices.
• Emerging markets: Larger discounts, but limited access due to supply chain and affordability issues.

Patent expirations in key markets, notably the U.S. (2024), threaten revenue streams by enabling biosimilar competitors.

What Are the Critical Revenue Drivers?

• New patient adoption: The rising global diabetes burden supports continued growth.
• Switching rates: Patients switching from other insulins or initiating therapy.
• Prescriber preferences: Endorsements from clinical guidelines influence uptake.
• Reimbursement policies: Favorable coverage improves accessibility and sales.

How Do Patent and Regulatory Changes Influence Revenue?

The U.S. patent for insulin detemir expired in March 2024, with biosimilar versions now available. These biosimilars typically retail at 30–50% below branded prices. The entry of biosimilars is expected to:

• Reduce average selling prices.
• Increase competitive pressure.
• Potentially lead to a 15–25% revenue decline in mature markets within the next 2 years.

Regulatory pathways, such as the Biosimilar User Fee Act (BsUFA), facilitate biosimilar approvals, accelerating market entry.

What Is the Outlook for Future Growth?

Clinical guidelines increasingly recommend basal insulin analogs for both type 1 and type 2 diabetes. The global insulin market, projected to grow at a CAGR of 7% from 2023 to 2030, underscores sustained demand.[4]

However, growth in insulin detemir sales may be constrained by:

• Market saturation in developed regions.
• Price competition from biosimilars.
• Emerging market price sensitivity.

Innovations like ultra-long-acting insulins and fixed-dose combinations threaten to shift patient preferences toward newer therapies.

How Will Market Competition Reshape Revenue?

Key competitors include:

Product	Manufacturer	Market Share (2022)	Price Point
Insulin glargine (Lantus)	Sanofi	35%	$85 per pen
Insulin degludec	Novo Nordisk	10%	$80 per pen
Biosimilar insulins	Multiple (generic)	12%	$45–$65 per pen

Predictions suggest biosimilar penetration will cause branded insulin detemir revenue to decline at an annual rate of 10–15% over the next three years.

Summary Equations and Assumptions

• Revenue in 2022: ( R_{2022} = P \times Q )

  where ( P ) is price per unit and ( Q ) is the number of units sold.

• Post-patent expiry revenue decline: ( R{2024+} = R{2023} \times (1 - d) )

  where ( d ) is the decline rate attributable to biosimilar entry (estimated at 20%).

Key Takeaways

• Insulin detemir commands significant market share in long-acting insulins, with annual sales around $2.4 billion.
• Patent expiration in 2024 and biosimilar entries are expected to reduce revenues by approximately 15–25% over the subsequent two years.
• Global insulin market growth sustains high demand, but price competition and evolving treatment guidelines are complicating prospects.
• Regulatory pathways and reimbursement strategies heavily influence market dynamics.
• Innovations and biosimilar competition will reshape revenue streams, necessitating strategic adaptation.

FAQs

1. What factors primarily influence insulin detemir sales decline post-patent expiry?
Biosimilar competition introduces lower-priced options, reducing overall market share and revenue. Payment negotiations and drug switching also impact sales.

2. How does biosimilar approval process affect market entry timelines?
Approval under biosimilar pathways typically takes 8–12 months post-application, accelerating competition.

3. Are there regional differences in biosimilar adoption?
Yes. Developed markets like the U.S. and EU show quicker adoption driven by reimbursement policies, while emerging markets lag due to pricing, supply, and regulatory hurdles.

4. What role do clinical guidelines play in maintaining insulin detemir’s market share?
Guidelines influence physician prescribing behaviors. Favorable inclusion supports continued use despite competition.

5. Which growth areas could offset declines from biosimilar entry?
Expansion in emerging markets and the development of combination therapies or ultra-long-acting insulins offer growth opportunities.

---

References

1. IQVIA, 2022. Global Insulin Sales Database.
2. International Diabetes Federation, 2021. IDF Diabetes Atlas, 10th ed.
3. American Diabetes Association, 2022. Standards of Medical Care in Diabetes.
4. Grand View Research, 2023. Insulin Market Size and Forecast.